Background {#Sec1}
==========

The rates of extended-spectrum beta-lactamase (ESBL)-production in *Klebsiella pneumoniae* are very high in hospitals worldwide, and highly resistant strains such as *K. pneumoniae* carbapenemase (KPC) or New Delhi metallo-beta-lactamase (NDM)-producing *K. pneumoniae* have been rapidly spreading between countries. Treatment of infections caused by multidrug-resistant *K. pneumoniae* has been a challenge, and there is increasing concern about the economic impact of these bacteria.

Serotype K1 *K. pneumoniae* has been reported as the predominant serotype among those isolates causing liver abscesses \[[@CR1], [@CR2]\]. Most K1 strains isolated from liver abscess cases belong to sequence type (ST) 23 in Asian countries \[[@CR3], [@CR4]\]. Although ESBL *K. pneumoniae* and KPC-producing *K. pneumoniae* have become globally widespread, a distinctive characteristic of K1 *K. pneumoniae* ST23 has been good susceptibility to most antibiotic classes (except ampicillin and piperacillin) \[[@CR5]\], however, ESBL-producing K1 *K. pneumoniae* strains have begun to be reported recently \[[@CR6], [@CR7]\]. In this study, we report serotype K1 *K. pneumoniae* strains co-producing the plasmid-mediated AmpC beta-lactamase (PAB) DHA-1 and ESBL.

Materials and methods {#Sec2}
=====================

Three ESBL-producing serotype K1 *K. pneumoniae* ST23 strains were identified from strains in the Asian Bacterial Bank (Asia Pacific Foundation for Infectious Diseases, Seoul, Korea), which had been collected during bacteremia studies in Korea between 2006 and 2008.

In vitro antimicrobial susceptibility testing was performed using the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@CR8]\]. Ten antimicrobial agents were tested, including ampicillin (AMP), amikacin (AMI), ceftazidime (CAZ), tetracycline (TET), cefepime (CPM), cefotaxime (CTX), ciprofloxacin (CIP), rifampicin (RIF), and piperacillin/tazobactam (P/T). For ESBL-positive candidates, which presented a ceftazidime or cefotaxime minimum inhibitory concentration (MIC) ≥2 mg/L, production of ESBL was confirmed by the double-disk synergy test using BBL™ Sensi-Disc™ kits (Becton Dickinson, Franklin Lakes, NJ, USA) according to CLSI guidelines \[[@CR8]\]. Quality control for ESBL production was performed using *E. coli* ATCC 25922 and *K. pneumoniae* ATCC 700603.

Double-disk synergy test-positive isolates were further tested by polymerase chain reaction (PCR) and sequence analyses to determine the gene responsible for the ESBL phenotype in the ESBL producers. In the ESBL-producing *K. pneumoniae* isolates, *bla* ~TEM~, *bla* ~SHV~, *bla* ~CTX-M~, *bla* ~GES~, *bla* ~PER~, and *bla* ~VEB~ genes were tested by PCR. In addition, *bla* ~DHA-1~, *bla* ~CMY~, *bla* ~FOX~, *bla* ~MOX,~ *bla* ~IMP~, *bla* ~VIM~, *bla* ~OXA~, and *bla* ~NDM~ genes were tested. The sequences were compared with those in the GenBank nucleotide database for subtyping.

To determine serotype K1, PCR was conducted using a primer pair specific for *mag*A, which is a gene specific for the K1 antigen. The primers were chosen as previously described: forward, 5′GGTGCTCTTTACATCATTGC-3′, and reverse, 5′-GCAATGGCCATTTGCGT TAG-3′ \[[@CR9]\]. Multilocus sequence typing (MLST) was conducted using the nucleotide sequences of seven housekeeping genes (*gagA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB*, and *tonB*) as previously described \[[@CR10]\]. For pulsed field gel electrophoresis (PFGE), agarose-embedded bacterial genomic DNA was digested with 20 U of *Xba*I. The restriction fragments were separated by gel electrophoresis in 0.5 × Tris-borate-EDTA buffer. Electrophoresis was performed using a CHEF Mapper XA (Bio-Rad Laboratories, Hercules, CA, USA). The PFGE patterns were analyzed using GelCompar II version 6.1 (Applied Maths, Belgium).

Results {#Sec3}
=======

Of the 120 *K. pneumoniae* isolates, 20 (16.7%) were ESBL-producers. Among the ESBL-producers, only three were determined to be serotype K1 (KPN1, KPN2, and KPN3). Antimicrobial susceptibilities of the three isolates are shown in Table [1](#Tab1){ref-type="table"}. All three strains were resistant to ampicillin, piperacillin-tazobactam, cefotaxime, ceftazidime, and rifampin. Two strains (KPN2 and KPN3) were also resistant to amikacin and ciprofloxacin. One strain (KPN2) was resistant to imipenem. In all three strains, no ESBL genes, including *bla* ~TEM~, *bla* ~SHV~, *bla* ~CTX-M~, *bla* ~GES~, *bla* ~PER~, and *bla* ~VEB~, were detected. Among the PAB genes (*bla* ~DHA-1~, *bla* ~CMY~, *bla* ~FOX~, and *bla* ~MOX~), only *bla* ~DHA-1~ was detected in two strains (KPN2 and KPN3). Carbapenemase genes were also not detected in all three isolates (Table [2](#Tab2){ref-type="table"}). Clonal relatedness was investigated by PFGE for the two strains. Analysis of the PFGE patterns showed that the two isolates carrying *bla* ~DHA-1~ were closely related (84% similarity).Table 1Antimicrobial susceptibilities in K1 *K. pneumoniae* ST23 strainsStrainMICs and antimicrobial susceptibilityAMPP/TCTXCAZCPMCIPAMITETIMIRIFKPN1\>64R\>256R16R\>64R\>64R0.125S4S1S0.5S64RKPN2\>64R\>256R32R\>64R32R4R\>128R4S4R64RKPN3\>64R\>256R32R\>64R0.5S2I\>128R2S0.125S64R*MIC* minimum inhibitory concentration, *R* resistant, *I* intermediate, *S* susceptible, *AMP* ampicillin, *P/T* piperacillin/tazobactam, *CTX* cefotaxime, *CAZ* ceftazidime, *CPM* cefepime, *CIP* ciprofloxacin, *AMI* amikacin, *TET* tetracycline, *IMI* imipenem, *RIF* rifampin Table 2Detection of ESBL genes and plasmid-mediated AmpC β-lactamase genes in K1 *K. pneumoniae* ST23 strainsStrainESBL genesPlasmid-mediated AmpC β-lactamase genesOthersTEMSHVCTX-MPERKPCPERVEBGES/IBCSMEIMI/NMCCMYACTFOXDHAACCMOXIMPVIMOXANDMKPN1\--^b^\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--KPN2-^a^-^b^\-\-\-\-\-\-\-\-\-\--DHA-1\-\-\-\-\--KPN3\--^b^\-\-\-\-\-\-\-\-\-\--DHA-1\-\-\-\-\--^a^TEM-1 (not an ESBL gene), ^b^SHV-11 (not an ESBL gene)

Discussion {#Sec4}
==========

Serotype K1 *K. pneumoniae* ST23 is, a highly virulent pathogenic strain causing invasive community-acquired infections, that is widespread in its geographical distribution in Asia \[[@CR5]\]. Fortunately, ST23 strains have shown good susceptibility to most antibiotics. However, the advent of multidrug resistance with high transmission potential in *K. pneumoniae* serotype K1 causes serious concerns. A few strains of ESBL-producing serotype K1 *K. pneumoniae* have already been reported in Asian countries \[[@CR6], [@CR7], [@CR11]\]. In the present study, we report serotype K1 *K. pneumoniae* strains co-producing the PAB DHA-1 and ESBL. We found three isolates that were phenotypically ESBL producers, but we could not detect any *bla* genes responsible for the ESBL phenotype. Therefore, other ESBL genotypes may be involved. In addition, two of the three isolates were identified as PAB. Recently, gram-negative organisms that produce both ESBLs and PAB enzymes have increasingly been described worldwide \[[@CR12]--[@CR15]\]. To our knowledge, this is the first report of serotype K1 *K. pneumoniae* producing both ESBL and PAB. Both ESBLs and PAB enzymes are associated with broad, multidrug resistance because multiple antibiotic-resistance genes exist on the same plasmid \[[@CR16]\]. One isolate (KPN3) in our study showed carbapenem resistance in the broth microdilution test. Subsequently, we used PCR analysis to determine the presence of carbapenemase genes, such as *bla* ~IMP~, *bla* ~VIM~, *bla* ~OXA~, and *bla* ~NDM~; however, none of these genes were detected. The frequency of PAB transmission may be higher than initially thought, especially if the spread of resistance mimics the trend that we have seen occurring over the past few years for ESBLs. Moreover, porin alteration, combined with the production of ESBL or PAB, has been demonstrated to confer carbapenem resistance \[[@CR17], [@CR18]\]. We also characterized antimicrobial susceptibility between non-serotype K1 and serotype K1 ESBL-producing *K. pneumoniae*. Although the number of total isolates was too small to draw definite conclusions, the resistant rates of piperacillin-tazobactam and imipenem in K1 isolates tended to be high. It is uncertain whether the increase of antimicrobial resistance in serotype K1 *K. pneumoniae* is connected with any one particular resistance gene.

The emergence of multidrug-resistant strains with high transmission potential in serotype K1 *K. pneumoniae* is of great concern due to limited alternative treatment options and the possibility of global dissemination. Careful surveillance of resistant strains and adequate infection prevention and control measures are necessary.

ESBL

:   Extended-spectrum beta-lactamase

PAB

:   Plasmid-mediated AmpC beta-lactamase

PFGE

:   Pulsed-field gel electrophoresis

KPC

:   *Klebsiella pneumoniae* carbapenemase

NDM

:   New Delhi metallo-beta-lactamase

CLSI

:   Clinical and Laboratory Standards Institute

MIC

:   Minimum inhibitory concentration

PCR

:   Polymerase chain reaction

A portion of this work was presented at the annual meeting of the Korean Society of Infectious Diseases in Jeju, South Korea on Nov 01, 2012.

Funding {#FPar1}
=======

The Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (2012R1A1A2006672), supported this research.

Availability of data and materials {#FPar2}
==================================

All the data supporting conclusions are available in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.

Authors' contributions {#FPar3}
======================

HSC and DRC performed the data collection. CL carried out the microbiological analysis. SHK, CK, KRP, and JS conceived the study, participated in its design and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

We used organisms from the Asian Bacterial Bank that had been collected during bacteremia studies in Korea. The Samsung Medical Center Institutional Review Board (2007-05-064) approved this study.
